Multimodal AI Approach May Predict Outcomes in Renal Cell Carcinoma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 348
- Publication type:
- Article
Works matching IS 08909091 AND DT 2024 AND VI 38 AND IP 9
Results: 11
1
2
Nivolumab Combo May Show Long-Term Benefits in Advanced RCC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 347
- By:
- Publication type:
- Article
3
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 339, doi. 10.46883/2024.25921026
- By:
- Publication type:
- Article
4
Starting at the Front Line in Metastatic Pancreatic Cancers: As New Options Emerge, How Do You Select and Sequence?
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 352
- By:
- Publication type:
- Article
5
Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 349
- By:
- Publication type:
- Article
6
Manageable AEs Noted in Belzutifan for Advanced RCC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 348
- Publication type:
- Article
7
Real-World Data Showcase Survival Outcomes After Immunotherapy/TKI Regimens in RCC.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 348
- By:
- Publication type:
- Article
8
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 336
- By:
- Publication type:
- Article
9
2024 Statistics May Impact Next Decade of Cancer Treatment.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 335
- By:
- Publication type:
- Article
10
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 345
- By:
- Publication type:
- Article
11
Publisher's Note.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 332
- By:
- Publication type:
- Article